Resources (2)

July 27, 2023

Manuscript: Analysis of Interleukin 8 Secretion by a Stem-Cell-Derived Human Intestinal Epithelial Monolayer Platform

Authors Yuli Wang and colleagues describe measurement of 8 cytokines released from stem cell-derived intestinal epithelium in response to exposure to the pro-inflammatory cytokine TNFa. The article shows results from using stem cells from 5 different regions of the intestine. The most responsive cytokine was IL-8 in all regions which could be blocked using common anti-inflammatory factors present in the gut.

July 26, 2023

Poster: GB004 Exhibits Protective Effects Directly on Epithelial Cells Using Ex Vivo Organoid and Monolayer Cultures

Client Kristin Taylor Meadows and colleagues from Gossamer Bio used RepliGut® Planar to established conditions for inducing inflammation response using TNFα. Using this model, they show how GB-004, a novel compound in development for treating ulcerative colitis reduced the destructive effects of TNFα on epithelial barrier integrity

July 26, 2023

Manuscript: Self-renewing Monolayer of Primary Colonic or Rectal Epithelial Cells

This 2018 Publication describes early work leading to establishment of RepliGut® Systems. In this manuscript, Dr. Yuli Wang and colleagues detail isolation of human stem cells and establishment of self-renewing monolayers of intestinal epithelial stem cells.

July 26, 2023

Manuscript: Evaluation of human primary intestinal monolayers for drug metabolizing capabilities

In this 2019 manuscript, Dr. Jennifer Speer and colleagues describe levels of CYP3A4, UGTs 2B17, 1A1 and 1A10, and CES2 proteins in freshly isolated intestinal crypts compared to 2 different monolayer intestinal epithelium formats derived from intestinal crypt stem cells. this work highlights the importants of the mechanical properties of the cell scaffold in maintaining intestinal epithelial cell metabolic functionality.

July 25, 2023

Poster: Primary Human Small Intestine Monolayers For Assessing Drug-Induced Intestinal Liabilities In Vitro

Presented at 2023 SOT meeting, collaborators from Janssen Pharmaceuticals describe using RepliGut® Planar Platform to distinguish between compounds with different potencies for the JNJ epigenetic target X with a known in vivo GI liability. The poster describes testing a limited set of reference compounds including drugs with a high (> 50%) and a low (0-4%) incidence of diarrhea in the clinic.